Table 2.
Compounds used in drug screenings assay.
| No. | Compound Name | Aliases | Class | Status in Clinical Trials |
|---|---|---|---|---|
| 1 | JQ1 | JQ-1[+] | BET inhibitor | Not evaluated |
| 2 | GSK525762 | I-BET762 | BET inhibitor | Phase 2 |
| 3 | EPZ-6438 | Tazemetostat | EZH2 inhibitor | Phase 3 |
| 4 | GSK2816126 | GSK-126 | EZH2 inhibitor | Phase 1 terminated prior to the completion due to an unfavorable benefit risk profile. |
| 5 | AZD2281 | Olaparib | PARP-1 inhibitor | FDA approved |
| 6 | BMN-673 | Talazoparib | PARP-1 inhibitor | FDA approved |
| 7 | PF-03814735 | - | Aurora Kinase Inhibitor | Phase 1 |
| 8 | PHA-739358 | Danusertib | Aurora Kinase Inhibitor | Phase 2 |